Topical Minoxidil Non-Responder Profile: Who Doesn't See Results and Why

Which groups the label itself excludes

A wide range of response, including little or none, is written into the labeling rather than being proof that something was done wrong [1][2].

The labels name specific situations where they say not to use the product, or where it may not work:

• The amount or pattern of hair loss is different from the picture on the carton. The women's label adds that the product "may not work for you" in that case [1][2].
• No family history of hair loss [1][2].
• Hair loss that is sudden or patchy [1][2].
• Not knowing the reason for the hair loss [1][2].
• Being under 18 [1][2].
• A scalp that is red, inflamed, infected, irritated or painful [1][2].
• Using other medicines on the scalp [1][2].
• Hair loss associated with childbirth, on the women's label [2].
• Any use by a woman of the men's 5% solution [1].

The labels list these as reasons not to use the products or as situations in which they may not work; they do not identify the cause of an individual's hair loss [1][2].

Area matters: the men's 5% solution is a vertex product

The men's 5% solution label covers the top of the scalp, the vertex, and states that the product "is not intended for frontal baldness or receding hairline" [1]. Applying it along a receding hairline is outside the labeled use. The same label directs one mL with the dropper twice a day directly onto the scalp in the hair loss area [1]. For women, the cited label covers 5% foam applied once daily [2].

Too early, and too much

Judging results too early can make treatment appear ineffective. The men's label says results may occur at 2 months and some men need at least 4 months; the women's foam label says results may occur at 3 months and some women need at least 6 months [1][2]. The men's label says to stop use and ask a doctor if there is no regrowth at 4 months, and the women's foam label says the same at 6 months [1][2].

Doubling up is not a rescue. Both labels state that using more or more often will not improve results [1][2], and the women's label says not to use more than directed [2]. Both also state that continued use is necessary to keep regrowth, or hair loss will begin again [1][2]. Hair that fills in and then thins after the product is dropped is the labeled behavior, not a late failure.

What the trials show, and what they do not

The largest controlled comparisons tested 5% against 2% and placebo:

• 393 men aged 18 to 49 used 5% solution (n=157), 2% solution (n=158) or placebo (n=78) twice daily for 48 weeks. The 5% group was significantly superior to both others on nonvellus hair count and on patient and investigator ratings of scalp coverage, with more pruritus and local irritation [5].
• 381 women aged 18 to 49 used 5% (n=153), 2% (n=154) or placebo (n=74) twice daily for 48 weeks. The 5% group beat placebo on all three primary measures [6].
• 352 men used a 5% foam or placebo for 16 weeks; hair counts favored the foam (P<.0001), and no efficacy data were collected past 16 weeks [7].

These are group averages. They show that 5% outperforms placebo across a treated group; they do not identify in advance which individual will be the person the label is describing.

Irritation and stopping early

Irritation shows up in the trials themselves: 5% solution produced more pruritus and local irritation in the men's trial [5], and more pruritus, irritation and hypertrichosis than 2% or placebo in the women's trial [6]. The labels say to stop use if scalp irritation or redness occurs, and not to use the product on a scalp that is already red, inflamed, infected, irritated or painful [1][2]. The 5% foam was formulated in a propylene glycol-free vehicle [7].

Oral minoxidil after topical: what has actually been compared

Oral minoxidil tablets are approved for severe hypertension, not hair loss, and the tablet label states that promoting hair growth is not an approved indication [8]. The topical 2% and 5% products, by contrast, are over-the-counter hair regrowth products [9].

A 2021 review in the Journal of the American Academy of Dermatology identified 17 studies involving 634 patients. It concluded that oral minoxidil appears effective and well tolerated in healthy patients who struggle with topical use, and that larger randomized dose-comparison studies were needed [11]. In a retrospective multicenter safety study of 1,404 patients treated for at least 3 months, with no control group, hypertrichosis occurred in 15.1%, lightheadedness in 1.7%, fluid retention in 1.3% and tachycardia in 0.9%; 1.2% stopped treatment because of systemic effects, and no life-threatening adverse effects were observed [10].

Two randomized trials compared oral with topical minoxidil in patients with androgenetic alopecia. Neither describes its participants as people who had already failed topical minoxidil:

• In a double-blind trial at one clinic in Brazil, 90 men were assigned to oral minoxidil 5 mg daily or topical 5% twice daily for 24 weeks; 68 completed. The reported between-group differences were not statistically significant [3].
• 65 patients were randomized to topical 5% or oral 1 mg daily for 6 months. Both groups improved hair diameter (P<0.001) with no significant difference between them [4].